Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis.
cirrhosis
hepatic encephalopathy
lactulose
Journal
BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
21
03
2021
revised:
26
04
2021
accepted:
06
05
2021
entrez:
19
5
2021
pubmed:
20
5
2021
medline:
25
11
2021
Statut:
ppublish
Résumé
Hepatic encephalopathy (HE) is defined as brain dysfunction that occurs because of acute liver failure or liver cirrhosis and is associated with significant morbidity and mortality. Lactulose is the standard of care till this date; however, polyethylene glycol (PEG) has gained the attention of multiple investigators. We screened five databases namely PubMed, Scopus, Web of Science, Cochrane Library and Embase from inception to 10 February 2021. Dichotomous and continuous data were analysed using the Mantel-Haenszel and inverse variance methods, respectively, which yielded a meta-analysis comparing PEG versus lactulose in the treatment of HE. Four trials with 229 patients were included. Compared with lactulose, the pooled effect size demonstrated a significantly lower average HE Scoring Algorithm (HESA) Score at 24 hours (Mean difference (MD)=-0.68, 95% CI (-1.05 to -0.31), p<0.001), a higher proportion of patients with reduction of HESA Score by ≥1 grade at 24 hours (risk ratio (RR)=1.40, 95% CI (1.17 to 1.67), p<0.001), a higher proportion of patients with a HESA Score of grade 0 at 24 hours (RR=4.33, 95% CI (2.27 to 8.28), p<0.0010) and a shorter time to resolution of HE group (MD=-1.45, 95% CI (-1.72 to -1.18), p<0.001) in favour of patients treated with PEG. PEG leads to a higher drop in the HESA Score and thus leads to a faster resolution of HE compared with lactulose.
Sections du résumé
BACKGROUND
Hepatic encephalopathy (HE) is defined as brain dysfunction that occurs because of acute liver failure or liver cirrhosis and is associated with significant morbidity and mortality. Lactulose is the standard of care till this date; however, polyethylene glycol (PEG) has gained the attention of multiple investigators.
METHODS
We screened five databases namely PubMed, Scopus, Web of Science, Cochrane Library and Embase from inception to 10 February 2021. Dichotomous and continuous data were analysed using the Mantel-Haenszel and inverse variance methods, respectively, which yielded a meta-analysis comparing PEG versus lactulose in the treatment of HE.
RESULTS
Four trials with 229 patients were included. Compared with lactulose, the pooled effect size demonstrated a significantly lower average HE Scoring Algorithm (HESA) Score at 24 hours (Mean difference (MD)=-0.68, 95% CI (-1.05 to -0.31), p<0.001), a higher proportion of patients with reduction of HESA Score by ≥1 grade at 24 hours (risk ratio (RR)=1.40, 95% CI (1.17 to 1.67), p<0.001), a higher proportion of patients with a HESA Score of grade 0 at 24 hours (RR=4.33, 95% CI (2.27 to 8.28), p<0.0010) and a shorter time to resolution of HE group (MD=-1.45, 95% CI (-1.72 to -1.18), p<0.001) in favour of patients treated with PEG.
CONCLUSION
PEG leads to a higher drop in the HESA Score and thus leads to a faster resolution of HE compared with lactulose.
Identifiants
pubmed: 34006606
pii: bmjgast-2021-000648
doi: 10.1136/bmjgast-2021-000648
pmc: PMC8137169
pii:
doi:
Substances chimiques
Polyethylene Glycols
3WJQ0SDW1A
Lactulose
4618-18-2
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Middle East J Dig Dis. 2017 Jan;9(1):12-19
pubmed: 28316761
Pharmacotherapy. 2010 May;30(5 Pt 2):28S-32S
pubmed: 20412038
Dig Dis Sci. 2008 Feb;53(2):529-38
pubmed: 17710551
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S7-S20
pubmed: 26041962
JAMA Intern Med. 2014 Nov;174(11):1727-33
pubmed: 25243839
Psychosom Med. 1998 Sep-Oct;60(5):550-6
pubmed: 9773757
Cochrane Database Syst Rev. 2004;(2):CD003044
pubmed: 15106187
Eur J Gastroenterol Hepatol. 2018 Dec;30(12):1476-1481
pubmed: 30234645
Clin Gastroenterol Hepatol. 2012 Sep;10(9):1034-41.e1
pubmed: 22642955
J Clin Gastroenterol. 2020 Oct 13;:
pubmed: 33060437
BMC Med Res Methodol. 2015 Apr 14;15:35
pubmed: 25880989
J Hepatol. 2011 May;54(5):1030-40
pubmed: 21145874
J Hepatol. 2015 Feb;62(2):437-47
pubmed: 25218789
Am J Med. 1971 Aug;51(2):148-59
pubmed: 5095524
ISRN Hepatol. 2014 Jun 04;2014:236268
pubmed: 27335836
Surgery. 2018 Jun;163(6):1324
pubmed: 29429578
Gastroenterology. 1977 Apr;72(4 Pt 1):573-83
pubmed: 14049
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Lancet. 1956 Oct 6;271(6945):689-94
pubmed: 13368499
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Hepatology. 2002 Mar;35(3):716-21
pubmed: 11870389
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120